




PICO 1: Is there important uncertainty about or variability in how much people/patients value the critical outcomes?




PICO 3: Is there important uncertainty about or variability in how much people/patients value the critical outcomes?




PICO 3: What would be the impact on health equity (prophylactic transfusion)?




PICO 3: What would be the impact on health equity (Iron therapy)?




PICO 3: What would be the impact on health equity (ESA(+iron therapy))?




PICO 3: Is prophylactic transfusion acceptable to key stakeholders




PICO 3: is Iron therapy acceptable to key stakeholders




PICO 3: Is ESA (+ iron therapy) acceptable to key stakeholders



PICO 3: Is prophylactic transfusion feasible to implement?



PICO 3: Is iron therapy feasible to implement?



PICO 3: Is ESA (+ iron therapy) feasible to implement?

